IMR Press / FBL / Volume 20 / Issue 7 / DOI: 10.2741/4353

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Infantile haemangioma: a complicated disease
Show Less
1 Department of General Surgery, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2015, 20(7), 1004–1016;
Published: 1 June 2015
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)

Infantile haemangiomas (IH) are common benign vascular tumors of childhood. They are characterised by rapid growth during the first year of life and slow regression that is usually completed by 7–10 years of age. The underlying mechanism of action of IH is aberrant angiogenesis and vasculogenesis, and involves the mammalian target of rapamycin pathway and vascular endothelial growth factor pathway. IH become a challenge if they are part of a syndrome, are located in certain areas of the body, or if complications develop. The beta-adrenergic receptor blocker propranolol is a promising new candidate for first-line systemic therapy. This review focuses on the clinical characteristics, pathogenesis and management of IH.

Infantile Haemangioma
Benign Vascular Tumor
Clinical Treatment
Back to top